Aprea Therapeutics Safety Review Committee Endorses Dosing Patients With ATRN-119 In ABOYA-119 Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
Aprea Therapeutics' Safety Review Committee has endorsed dosing patients with ATRN-119 in the ABOYA-119 clinical trial. ATRN-119, a macrocyclic ATR inhibitor, has shown safety and tolerance through the first 5 cohorts with no dose-limiting toxicities. The company is on track to complete dose escalation and potentially generate initial human efficacy data in the second half of 2024.
May 28, 2024 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aprea Therapeutics' ATRN-119 has shown promising safety results in the ABOYA-119 clinical trial, with no dose-limiting toxicities observed. The company is on track to complete dose escalation and potentially generate initial human efficacy data in the second half of 2024.
The positive safety results and the potential for initial human efficacy data in the near future are likely to boost investor confidence in Aprea Therapeutics. This could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100